You just read:

SELLAS™ Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia (AML) and Malignant Pleural Mesothelioma (MPM), as Presented at the 2016 ASCO Annual Meeting

News provided by

SELLAS Life Sciences Group

Jun 06, 2016, 08:00 ET